– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatment of Duche ...

Investor Martin Shkreli’s big biotech short position is blowing up after the stock’s monumental rally over the past week, following a major clinical catalyst. Popularly known as “Pharma bro,” Shkreli initiated a short position against California-based Capricor Therapeutics Inc. (NASDAQ: CAPR) two weeks ago, referring to the company’s HOPE-3 cell therapy for Duchenne Muscular Dystrophy as “COPE-3.”“It will not work. This is the company's only asset,” Shkreli said, yet the company cleared a major regulatory h ...

Capricor Therapeutics (NASDAQ:CAPR) is conducting a public offering of common stock to fund the advancement of its product candidates, including Deramiocel for DMD.Analysts from Maxim Group and H.C. Wainwright have set optimistic price targets for CAPR, suggesting a potential increase of approximately 98.56% and 99.65%, respectively.The company's stock has shown volatility but maintains a strong market capitalization of approximately $1.23 billion, indicating significant investor interest.Capricor Therapeut ...

Core Points - Capricor Therapeutics is hosting a conference call to discuss the HOPE-3 Phase III Topline Data [1] Group 1 - The call is being led by AJ Bergmann, the Chief Financial Officer of Capricor [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Capricor Therapeutics (CAPR) shares surged 281.9% this week following positive results from a late-stage study of deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][6] - Deramiocel is the company's lead product candidate and the only asset in its clinical pipeline, representing an investigational, allogeneic cardiac-derived cell therapy [1] Study Details - The phase III HOPE-3 study involved 106 boys and young men with DMD, averaging 15 years old, who received either intravenous deramiocel at 150 million cells per infusion or placebo every three months for a year while on stable corticosteroid therapy [2] - The study demonstrated a 54% slowing of disease progression in upper-limb function compared to placebo, indicating significant preservation of daily functional abilities [3] - The study also achieved a 91% slowing in the deterioration of left-ventricular ejection fraction, addressing a major unmet need in DMD patients [4] Market Performance - Over the past year, Capricor Therapeutics shares have increased by 71%, contrasting with a 0.8% decline in the industry [5] Regulatory Context - In July 2025, Capricor faced a regulatory setback when the FDA issued a complete response letter (CRL) regarding the biologics license application (BLA) for deramiocel, citing insufficient clinical evidence [9][10] - The company believes the new phase III HOPE-3 results strengthen deramiocel's clinical profile and plans to submit a formal response to the FDA, which had indicated that positive findings could support resubmission [11][12] Disease Context - DMD is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., primarily boys, leading to progressive muscle loss and often resulting in cardiomyopathy and heart failure [13]

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts and ...

Capricorn Therapeutics (CAPR) shares more than quadrupled on Dec. 3 after the biotech company announced late-stage HOPE-3 clinical trial results for deramiocel, its investigational treatment for Duchenne Muscular Dystrophy. The positive results prompted notable short-seller Martin Shkreli to publicly acknowledge his “bad call” on CAPR, reversing his earlier prediction that the HOPE-3 trial would fail. More News from Barchart His admission underscores the binary nature of biotech investments, where succe ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Snowflake Inc (NYSE:SNOW) fell sharply in pre-market trading after posting quarterly results.Snowflake delivered third-quarter revenue of $1.21 billion, beating analyst estimates of $1.18 billion, according to Benzinga Pro. The AI data cloud company reported adjusted earnings of 35 cents per share for the period, beating analyst estimates of 31 cents per share.Snowflake shares dipped 8.6% to $241.85 in ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Snowflake Inc (NYSE:SNOW) fell sharply in pre-market trading after posting quarterly results.Snowflake delivered third-quarter revenue of $1.21 billion, beating analyst estimates of $1.18 billion, according to Benzinga Pro. The AI data cloud company reported adjusted earnings of 35 cents per share for the period, beating analyst estimates of 31 cents per share.Snowflake shares dipped 8.6% to $241.85 in ...